The analysis of potential genomic biomarkers of immunotherapy in 1000 Chinese patients with cancer showed that lung cancer patients with EGFR mutations had significantly lower TMB than those with wild-type EGFR [36]. This evidence concerns the gene EGFR and lung carcinoma.